Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 13/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.32 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | CYP8B1 | Q9UNU6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1969823 | 0.92 | P2RY12 (0.49) | P2RY12NOTUMDPP4DPP8DPP9 | |
| SCHEMBL1968039 | 0.82 | P2RY12 (0.42) | P2RY12NOTUMDPP4HDAC6BRD4 | |
| SCHEMBL1970024 | 0.80 | P2RY12 (0.62) | P2RY12NOTUM | |
| SCHEMBL12409406 | 0.75 | P2RY12 (0.65) | P2RY12NOTUMDPP4DPP8DPP9 | |
| SCHEMBL1968886 | 0.74 | P2RY12 (0.51) | P2RY12NOTUMDPP4DPP8DPP9 | |
| SCHEMBL1973330 | 0.74 | P2RY12 (0.57) | P2RY12NOTUMDPP4DPP8DPP9 | |
| SCHEMBL1968830 | 0.74 | P2RY12 (0.43) | P2RY12DPP4CYP8B1 | |
| SCHEMBL1968832 | 0.74 | P2RY12 (0.43) | P2RY12DPP4CYP8B1 | |
| SCHEMBL1968194 | 0.73 | P2RY12 (0.43) | P2RY12DPP4HDAC6 | |
| SCHEMBL12491306 | 0.73 | P2RY12 (0.40) | P2RY12NOTUMDPP4DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166121-A1 | FUSED HETEROCYCLIC COMPOUND | LG LIFE SCIENCES LTD. (KR) | 2011-07-07 | — | — | US | disclosed |
| US-20110166121-A1 | FUSED HETEROCYCLIC COMPOUND | LG LIFE SCIENCES LTD. (KR) | 2011-07-07 | — | — | US | disclosed |
| US-20110166121-A1 | FUSED HETEROCYCLIC COMPOUND | LG LIFE SCIENCES LTD. (KR) | 2011-07-07 | — | — | US | disclosed |
| EP-2334689-A2 | FUSED HETEROCYCLIC COMPOUND | LG Life Sciences Ltd. (KR) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010027236-A2 | FUSED HETEROCYCLIC COMPOUND | LG LIFE SCIENCES LTD. (KR) | 2010-03-11 | — | — | WO | disclosed |
| WO-2010027236-A2 | FUSED HETEROCYCLIC COMPOUND | LG LIFE SCIENCES LTD. (KR) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166121-A1 | FUSED HETEROCYCLIC COMPOUND | F2, PF4, F11 | P2RY12 127/4885NOTUM 107/4885DPP4 1926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.